Study details
Enrolling now
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
Nader Sanai
NCT IDNCT05773326ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
12
Study length
about 5 years
Ages
18+
Locations
1 site in AZ
What this study is about
This trial is testing a new treatment called temsirolimus for people with recurrent, high-grade gliomas. Participants will receive a single infusion of temsirolimus through the artery supplying the tumor or intravenously.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Temsirolimus
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IVInjection / IV
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
temsirolimus
Drug routes
injection, intravenous
Endpoints
Primary: Tumor pharmacokinetics (PK) of temsirolimus
Secondary: Pharmacodynamic effects of temsirolimus
Body systems
Oncology